Brian A. Ference, MD, MPhil, MSc, FACC

Brian Ference

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Merck & Co., Inc.(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Ionis Pharmaceuticals(SIGNIFICANT), American College of Cardiology(SIGNIFICANT), Regeneron(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT), European Atherosclerosis Society(SIGNIFICANT), European Society of Cardiology(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), The Medicines Company(SIGNIFICANT), KrKa Phamaceuticals(SIGNIFICANT), Mylan Inc.(MODEST), Pfizer Inc(MODEST) RESEARCH/RESEARCH GRANTS: Merck & Co., Inc.(SIGNIFICANT), Esperion(SIGNIFICANT), Amgen(SIGNIFICANT), Novartis Corporation(SIGNIFICANT)

View Full Disclosure